Rad51 siRNA delivered by HVJ envelope vector enhances the anti‐cancer effect of cisplatin

Every cancer therapy appears to be transiently effective for cancer regression, but cancers gradually transform to be resistant to the therapy. Cancers also develop machineries to resist chemotherapy. Short interfering RNA (siRNA) has been evaluated as an attractive and effective tool for suppressing a target protein by specifically digesting its mRNA. Suppression of the machineries using siRNA may enhance the sensitivity to chemotherapy in cancers when combined with an effective delivery system.

[1]  S. Kanno,et al.  Effect of DNA-damaging agents on DNA replication and cell-cycle progression of cultured mouse mammary carcinoma cells. , 1985, Japanese journal of cancer research : Gann.

[2]  J. Roberts,et al.  Potentiation of sulphur mustard or cisplatin-induced toxicity by caffeine in Chinese hamster cells correlates with formation of DNA double-strand breaks during replication on a damaged template. , 1986, Mutation research.

[3]  P. Hasty,et al.  A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53 , 1996, Molecular and cellular biology.

[4]  T. Ohnishi,et al.  In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. , 1998, Biochemical and biophysical research communications.

[5]  E. Venkatraman,et al.  BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). , 1998, Cancer research.

[6]  R. Brown,et al.  Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs , 1999, Expert Reviews in Molecular Medicine.

[7]  J. Bourhis,et al.  Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen. , 1999, Molecular pharmacology.

[8]  R. Britten,et al.  Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumour cells , 1999, British Journal of Cancer.

[9]  R. Weichselbaum,et al.  The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin* , 2000, The Journal of Biological Chemistry.

[10]  M. Marinus,et al.  Multiple pathways of recombination define cellular responses to cisplatin. , 2000, Chemistry & biology.

[11]  Y. Kaneda,et al.  Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1β mediated by a tumor-specific vector, HVJ cationic liposomes , 2001, Cancer Gene Therapy.

[12]  W. K. Myint,et al.  Examining the non-homologous repair process following cisplatin and radiation treatments , 2002, International journal of radiation biology.

[13]  Tomoyuki Nishikawa,et al.  Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  T. Myers,et al.  DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program , 2002, Anti-cancer drugs.

[15]  T. Chow,et al.  An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. , 2002, Cancer research.

[16]  A. Duncan,et al.  Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. , 2002, Cancer research.

[17]  Y. Kaneda,et al.  Inhibitory Effects of Novel AP-1 Decoy Oligodeoxynucleotides on Vascular Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo , 2002, Circulation research.

[18]  H. Liber,et al.  Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. , 2002, Cancer research.

[19]  S. Freier,et al.  Elevated levels of Rad51 recombination protein in tumor cells. , 2002, Cancer research.

[20]  W. Dynan,et al.  Reconstitution of the mammalian DNA double-strand break end-joining reaction reveals a requirement for an Mre11/Rad50/NBS1-containing fraction. , 2002, Nucleic acids research.

[21]  N. Déglon,et al.  Lentiviral-mediated RNA interference. , 2002, Human gene therapy.

[22]  David J. Chen,et al.  Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line. , 2002, DNA repair.

[23]  Masataka Harada,et al.  Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40 , 2003, Nature.

[24]  A. D’Andrea,et al.  The Fanconi anaemia/BRCA pathway , 2003, Nature Reviews Cancer.

[25]  K. Camphausen,et al.  Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. , 2003, Cancer research.

[26]  P. Karran,et al.  Vanillins--a novel family of DNA-PK inhibitors. , 2003, Nucleic acids research.

[27]  K. Taira,et al.  Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. , 2003, Antisense & nucleic acid drug development.

[28]  T. Helleday,et al.  The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer , 2003, International journal of cancer.

[29]  S. Kaye,et al.  Drug resistance reversal--are we getting closer? , 2003, European journal of cancer.

[30]  T. Fojo,et al.  Strategies for reversing drug resistance , 2003, Oncogene.

[31]  T. DeWeese,et al.  Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. , 2003, Cancer research.

[32]  H. Stürzbecher,et al.  Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. , 2003, Toxicology.

[33]  M. Sioud.  Ribozyme- and siRNA-mediated mRNA degradation: a general introduction. , 2004, Methods in molecular biology.

[34]  C. Sherr,et al.  Principles of Tumor Suppression , 2004, Cell.

[35]  De-Pei Liu,et al.  Retrovirus vector-mediated stable gene silencing in human cell. , 2004, Biochemical and biophysical research communications.

[36]  Y. Kaneda,et al.  Intrathecal injection of HVJ‐E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairment in rats , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  P. Glazer,et al.  Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W. Holleran,et al.  Evolution of high-dose cisplatin , 1988, Investigational New Drugs.

[39]  T. Hino,et al.  siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme. , 2004, Biochemical and biophysical research communications.

[40]  G. Broggi,et al.  Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients , 2004, Journal of Neuro-Oncology.

[41]  Thomas Tuschl,et al.  siRNAs: applications in functional genomics and potential as therapeutics , 2004, Nature Reviews Drug Discovery.

[42]  R. Plasterk,et al.  Dicers at RISC The Mechanism of RNAi , 2004, Cell.